📊 XAGEW Key Takeaways
Is Longevity Health Holdings, Inc. (XAGEW) a Good Investment?
Longevity Health Holdings exhibits severe financial distress with negative stockholders' equity (-$5.9M), critical liquidity ratios (current ratio 0.25x), and negative operating cash flow (-$3.3M) despite impressive revenue growth. The company is technically insolvent with insufficient liquid assets to cover liabilities, representing high bankruptcy risk within 12 months.
Why Buy Longevity Health Holdings, Inc. Stock? XAGEW Key Strengths
- Exceptional gross margin of 57.2% indicates viable product-market fit and unit economics
- Explosive revenue growth of 3,701% YoY demonstrates strong early-stage demand
- Cash position of $706.7K provides minimal short-term operational runway
XAGEW Stock Risks: Longevity Health Holdings, Inc. Investment Risks
- Negative stockholders' equity of -$5.9M indicates technical insolvency and balance sheet deterioration
- Critical liquidity crisis with current ratio of 0.25x and quick ratio of 0.12x; unable to meet short-term obligations
- Negative operating cash flow of -$3.3M with only $706.7K cash; company burning cash at unsustainable rate relative to reserves
- Excessive debt burden with $9.4M long-term debt exceeding total assets of $2.4M by 3.9x
- Deep operating losses (margin -371.6%) and negative net income despite revenue growth; burn rate accelerating faster than revenue scaling
Key Metrics to Watch
- Stockholders' equity trajectory and timeline to positive equity through capital raise or profitability
- Operating cash flow sustainability and cash runway at current burn rate
- Debt maturity schedule and refinancing requirements; default risk on $9.4M long-term debt
- Operating expense ratio and path to operating profitability relative to revenue growth
- Capital adequacy and dilution from emergency financing rounds needed to avoid insolvency
Longevity Health Holdings, Inc. (XAGEW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
XAGEW Profit Margin, ROE & Profitability Analysis
XAGEW vs Consumer Sector: How Longevity Health Holdings, Inc. Compares
How Longevity Health Holdings, Inc. compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Longevity Health Holdings, Inc. Stock Overvalued? XAGEW Valuation Analysis 2026
Based on fundamental analysis, Longevity Health Holdings, Inc. has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Longevity Health Holdings, Inc. Balance Sheet: XAGEW Debt, Cash & Liquidity
XAGEW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Longevity Health Holdings, Inc.'s revenue has grown significantly by 3,701% over the 5-year period, indicating strong business expansion. The most recent EPS of $-14.56 indicates the company is currently unprofitable.
XAGEW Revenue Growth, EPS Growth & YoY Performance
XAGEW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $20.5K | -$1.4M | $-0.83 |
| Q2 2025 | $12.3K | -$1.9M | $-1.56 |
| Q1 2025 | N/A | -$1.5M | $-1.52 |
| Q3 2024 | N/A | -$2.9M | $-0.14 |
| Q2 2024 | N/A | -$3.3M | $-0.16 |
| Q3 2023 | N/A | -$5.9M | $-0.62 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Longevity Health Holdings, Inc. Dividends, Buybacks & Capital Allocation
XAGEW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Longevity Health Holdings, Inc. (CIK: 0001842939)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XAGEW
What is the AI rating for XAGEW?
Longevity Health Holdings, Inc. (XAGEW) has an AI rating of STRONG SELL with 97% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XAGEW's key strengths?
Claude: Exceptional gross margin of 57.2% indicates viable product-market fit and unit economics. Explosive revenue growth of 3,701% YoY demonstrates strong early-stage demand.
What are the risks of investing in XAGEW?
Claude: Negative stockholders' equity of -$5.9M indicates technical insolvency and balance sheet deterioration. Critical liquidity crisis with current ratio of 0.25x and quick ratio of 0.12x; unable to meet short-term obligations.
What is XAGEW's revenue and growth?
Longevity Health Holdings, Inc. reported revenue of $1.9M.
Does XAGEW pay dividends?
Longevity Health Holdings, Inc. does not currently pay dividends.
Where can I find XAGEW SEC filings?
Official SEC filings for Longevity Health Holdings, Inc. (CIK: 0001842939) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XAGEW's EPS?
Longevity Health Holdings, Inc. has a diluted EPS of $-4.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XAGEW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Longevity Health Holdings, Inc. has a STRONG SELL rating with 97% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XAGEW stock overvalued or undervalued?
Valuation metrics for XAGEW: ROE of N/A (sector avg: 18%), net margin of -361.0% (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy XAGEW stock in 2026?
Our dual AI analysis gives Longevity Health Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XAGEW's free cash flow?
Longevity Health Holdings, Inc.'s operating cash flow is $-3.3M, with capital expenditures of $14.2K. FCF margin is -174.8%.
How does XAGEW compare to other Consumer stocks?
Vs Consumer sector averages: Net margin -361.0% (avg: 8%), ROE N/A (avg: 18%), current ratio 0.25 (avg: 1.5).